Beijing Chest Hospital, Capital Medical University

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC

Phase 2

Recruiting

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Adebrelimab plus albumin-bound paclitaxel, carboplatin and recaticimab

First Posted Date: 2024-06-21

Last Posted Date: 2024-12-16

Lead Sponsor: Beijing Chest Hospital, Capital Medical University

Target Recruit Count: 35

Registration Number: NCT06467617

Locations: 🇨🇳
Beijing Chest Hospital, Beijing, Beijing, China

PD-L1/PD-1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone for the Neoadjuvant Treatment of Limited-stage SCLC

Phase 2

Not yet recruiting

Conditions: Limited-stage Small-cell Lung Cancer

Interventions: Drug: Carboplatin injection
Drug: Tislelizumab
Drug: Cisplatin injection
Drug: Etoposide injection

First Posted Date: 2024-04-19

Last Posted Date: 2024-04-19

Lead Sponsor: Beijing Chest Hospital, Capital Medical University

Target Recruit Count: 60

Registration Number: NCT06375109

Prev
1
Next

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy